Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
94.827,26
-0,30%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Equillium Inc (EQ) Equillium Inc (EQ) Notizie

EQ

Equillium (EQ)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EQ
DataOraFonteTitoloSimboloCompagnia
13/12/202422:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
12/12/202423:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
12/12/202423:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EQEquillium Inc
15/11/202403:50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EQEquillium Inc
13/11/202422:01Business WireEquillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:EQEquillium Inc
13/11/202414:00Business WireEquillium to Present at the Stifel Healthcare ConferenceNASDAQ:EQEquillium Inc
12/11/202414:00Business WireEquillium Announces Poster Presentation at the Society for Immunotherapy of CancerNASDAQ:EQEquillium Inc
31/10/202417:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EQEquillium Inc
31/10/202412:00Business WireEquillium Maintains Rights to Itolizumab Following Ono PartnershipNASDAQ:EQEquillium Inc
07/10/202414:00Business WireEquillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of CancerNASDAQ:EQEquillium Inc
10/09/202414:00Business WireEquillium to Present at the Stifel Virtual Inflammation & Immunology SummitNASDAQ:EQEquillium Inc
04/09/202414:00Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EQEquillium Inc
28/08/202414:00Business WireEquillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceNASDAQ:EQEquillium Inc
08/08/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQEquillium Inc
08/08/202422:01Business WireEquillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical HighlightsNASDAQ:EQEquillium Inc
06/08/202414:00Business WireEquillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseNASDAQ:EQEquillium Inc
18/07/202419:57Business WireEquillium Announces Second Quarter 2024 Estimated Cash and Investments BalanceNASDAQ:EQEquillium Inc
02/07/202414:00Business WireEquillium to Participate in Upcoming Investor ConferencesNASDAQ:EQEquillium Inc
12/06/202414:00Business WireEquillium to be included in the Russell Microcap® IndexNASDAQ:EQEquillium Inc
04/06/202414:00Business WireEquillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia AreataNASDAQ:EQEquillium Inc
29/05/202414:00Business WireEquillium to Present at the Jefferies Global Healthcare ConferenceNASDAQ:EQEquillium Inc
14/05/202414:00Business WireEquillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseNASDAQ:EQEquillium Inc
09/05/202422:01Business WireEquillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical HighlightsNASDAQ:EQEquillium Inc
07/05/202414:00Business WireEquillium Announces Poster Presentation at the Annual Meeting of The American Association of ImmunologistsNASDAQ:EQEquillium Inc
01/04/202414:00Business WireEquillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus NephritisNASDAQ:EQEquillium Inc
25/03/202421:01Business WireEquillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical HighlightsNASDAQ:EQEquillium Inc
22/03/202413:00Business WireEquillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational ConferenceNASDAQ:EQEquillium Inc
23/02/202423:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EQEquillium Inc
21/12/202314:00Business WireEquillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac DiseaseNASDAQ:EQEquillium Inc
20/11/202317:23PR Newswire (US)EQ Bank Card launches in Québec as Carte Banque EQNASDAQ:EQEquillium Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EQ

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
SPM
Saipem
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
TEN
Tenaris
BIT
MONC
Moncler
BIT
FBK
Finecobank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network